APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Outlook and Growth Opportunities 2026

23 December 2025203 pages

Choose your research edition.

Industry ResearchDrugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market include Takeda Pharmaceutical, CSPC, Shenzhen Lijian Pharmaceutical, Sanofi, Merck & Co., Inc. (USA), Roche, Pfizer Inc. (USA), NCPC and Sinopharm Group, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market.

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Company

Takeda Pharmaceutical

CSPC

Shenzhen Lijian Pharmaceutical

Sanofi

Merck & Co., Inc. (USA)

Roche

Pfizer Inc. (USA)

NCPC

Sinopharm Group

GlaxoSmithKline plc (UK)

Daiichi Sankyo

Bayer

AbbVie

Sun Pharmaceutical

Lupin

Hikma Pharmaceuticals

Dr. Reddy's Laboratories

Cipla

Celltrion

Astellas Pharma Inc. (Japan)

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Type

Ceftriaxone

Doxycycline

Other

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Application

Retail Pharmacy

Hospital

Other

Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae key companies, revenue, market share, and recent developments.

3. To split the Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae industry.

Chapter 3: Detailed analysis of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Trends Table 2. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Drivers Table 3. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Opportunities and Challenges Table 4. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Restraints Table 5. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue Share by Company (2021-2026) Table 7. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Key Company Manufacturing Base & Headquarters Table 9. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Company, Product Type & Application Table 10. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Ceftriaxone Table 15. Significant Companies of Doxycycline Table 16. Significant Companies of Other Table 17. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type (2021-2026) Table 21. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Retail Pharmacy Table 23. Significant Companies of Hospital Table 24. Significant Companies of Other Table 25. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application (2021-2026) Table 29. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application (2027-2032) Table 30. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Region (2021-2026) Table 33. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Region (2027-2032) Table 35. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Market Share by Country (2021-2026) Table 38. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Market Share by Country (2027-2032) Table 40. Takeda Pharmaceutical Company Information Table 41. Takeda Pharmaceutical Business Overview Table 42. Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 44. Takeda Pharmaceutical Recent Development Table 45. CSPC Company Information Table 46. CSPC Business Overview Table 47. CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 49. CSPC Recent Development Table 50. Shenzhen Lijian Pharmaceutical Company Information Table 51. Shenzhen Lijian Pharmaceutical Business Overview Table 52. Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 54. Shenzhen Lijian Pharmaceutical Recent Development Table 55. Sanofi Company Information Table 56. Sanofi Business Overview Table 57. Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 59. Sanofi Recent Development Table 60. Merck & Co., Inc. (USA) Company Information Table 61. Merck & Co., Inc. (USA) Business Overview Table 62. Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 64. Merck & Co., Inc. (USA) Recent Development Table 65. Roche Company Information Table 66. Roche Business Overview Table 67. Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 69. Roche Recent Development Table 70. Pfizer Inc. (USA) Company Information Table 71. Pfizer Inc. (USA) Business Overview Table 72. Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 74. Pfizer Inc. (USA) Recent Development Table 75. NCPC Company Information Table 76. NCPC Business Overview Table 77. NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 79. NCPC Recent Development Table 80. Sinopharm Group Company Information Table 81. Sinopharm Group Business Overview Table 82. Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 84. Sinopharm Group Recent Development Table 85. GlaxoSmithKline plc (UK) Company Information Table 86. GlaxoSmithKline plc (UK) Business Overview Table 87. GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 89. GlaxoSmithKline plc (UK) Recent Development Table 90. Daiichi Sankyo Company Information Table 91. Daiichi Sankyo Business Overview Table 92. Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 94. Daiichi Sankyo Recent Development Table 95. Bayer Company Information Table 96. Bayer Business Overview Table 97. Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 99. Bayer Recent Development Table 100. AbbVie Company Information Table 101. AbbVie Business Overview Table 102. AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 104. AbbVie Recent Development Table 105. Sun Pharmaceutical Company Information Table 106. Sun Pharmaceutical Business Overview Table 107. Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 109. Sun Pharmaceutical Recent Development Table 110. Lupin Company Information Table 111. Lupin Business Overview Table 112. Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 114. Lupin Recent Development Table 115. Hikma Pharmaceuticals Company Information Table 116. Hikma Pharmaceuticals Business Overview Table 117. Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 119. Hikma Pharmaceuticals Recent Development Table 120. Dr. Reddy's Laboratories Company Information Table 121. Dr. Reddy's Laboratories Business Overview Table 122. Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 124. Dr. Reddy's Laboratories Recent Development Table 125. Cipla Company Information Table 126. Cipla Business Overview Table 127. Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 129. Cipla Recent Development Table 130. Celltrion Company Information Table 131. Celltrion Business Overview Table 132. Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 134. Celltrion Recent Development Table 135. Astellas Pharma Inc. (Japan) Company Information Table 136. Astellas Pharma Inc. (Japan) Business Overview Table 137. Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio Table 139. Astellas Pharma Inc. (Japan) Recent Development Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Image Figure 2. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Ceftriaxone Image Figure 8. Doxycycline Image Figure 9. Other Image Figure 10. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type (2021-2032) Figure 13. Retail Pharmacy Image Figure 14. Hospital Image Figure 15. Other Image Figure 16. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application (2021-2032) Figure 19. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032) & (US$ Million) Figure 22. North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032) & (US$ Million) Figure 28. South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Ceftriaxone
  • Doxycycline
  • Other
Applications
  • Retail Pharmacy
  • Hospital
  • Other
Companies covered
  • Takeda Pharmaceutical
  • CSPC
  • Shenzhen Lijian Pharmaceutical
  • Sanofi
  • Merck & Co., Inc. (USA)
  • Roche
  • Pfizer Inc. (USA)
  • NCPC
  • Sinopharm Group
  • GlaxoSmithKline plc (UK)
  • Daiichi Sankyo
  • Bayer
  • AbbVie
  • Sun Pharmaceutical
  • Lupin
  • Hikma Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Cipla
  • Celltrion
  • Astellas Pharma Inc. (Japan)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Dynamics
  1. 2.1 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Trends
  2. 2.2 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Drivers
  3. 2.3 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Opportunities and Challenges
  4. 2.4 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Industry Restraints
3 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market by Company
  1. 3.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Company Ranking (2024-2026)
  4. 3.4 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Company Product Type and Application
  6. 3.6 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market by Type
  1. 4.1 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Type Introduction
  2. 4.1.1 Ceftriaxone
  3. 4.1.2 Doxycycline
  4. 4.1.3 Other
  5. 4.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Type
  6. 4.2.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Type (2021-2032)
  8. 4.2.3 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type (2021-2032)
5 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Market by Application
  1. 5.1 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Other
  5. 5.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Application
  6. 5.2.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application (2021-2032)
6 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Regional Value Analysis
  1. 6.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032)
  7. 6.3.2 North America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032)
  16. 6.6.2 South America Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Country, 2025 VS 2032
7 Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Country-level Value Analysis
  1. 7.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 CSPC
  8. 8.2.1 CSPC Company Information
  9. 8.2.2 CSPC Business Overview
  10. 8.2.3 CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  12. 8.2.5 CSPC Recent Developments
  13. 8.3 Shenzhen Lijian Pharmaceutical
  14. 8.3.1 Shenzhen Lijian Pharmaceutical Company Information
  15. 8.3.2 Shenzhen Lijian Pharmaceutical Business Overview
  16. 8.3.3 Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shenzhen Lijian Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  18. 8.3.5 Shenzhen Lijian Pharmaceutical Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Merck & Co., Inc. (USA)
  26. 8.5.1 Merck & Co., Inc. (USA) Company Information
  27. 8.5.2 Merck & Co., Inc. (USA) Business Overview
  28. 8.5.3 Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co., Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  30. 8.5.5 Merck & Co., Inc. (USA) Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Pfizer Inc. (USA)
  38. 8.7.1 Pfizer Inc. (USA) Company Information
  39. 8.7.2 Pfizer Inc. (USA) Business Overview
  40. 8.7.3 Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc. (USA) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  42. 8.7.5 Pfizer Inc. (USA) Recent Developments
  43. 8.8 NCPC
  44. 8.8.1 NCPC Company Information
  45. 8.8.2 NCPC Business Overview
  46. 8.8.3 NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NCPC Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  48. 8.8.5 NCPC Recent Developments
  49. 8.9 Sinopharm Group
  50. 8.9.1 Sinopharm Group Company Information
  51. 8.9.2 Sinopharm Group Business Overview
  52. 8.9.3 Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sinopharm Group Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  54. 8.9.5 Sinopharm Group Recent Developments
  55. 8.10 GlaxoSmithKline plc (UK)
  56. 8.10.1 GlaxoSmithKline plc (UK) Company Information
  57. 8.10.2 GlaxoSmithKline plc (UK) Business Overview
  58. 8.10.3 GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline plc (UK) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  60. 8.10.5 GlaxoSmithKline plc (UK) Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 AbbVie
  74. 8.13.1 AbbVie Company Information
  75. 8.13.2 AbbVie Business Overview
  76. 8.13.3 AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AbbVie Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  78. 8.13.5 AbbVie Recent Developments
  79. 8.14 Sun Pharmaceutical
  80. 8.14.1 Sun Pharmaceutical Company Information
  81. 8.14.2 Sun Pharmaceutical Business Overview
  82. 8.14.3 Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Sun Pharmaceutical Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  84. 8.14.5 Sun Pharmaceutical Recent Developments
  85. 8.15 Lupin
  86. 8.15.1 Lupin Company Information
  87. 8.15.2 Lupin Business Overview
  88. 8.15.3 Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Lupin Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  90. 8.15.5 Lupin Recent Developments
  91. 8.16 Hikma Pharmaceuticals
  92. 8.16.1 Hikma Pharmaceuticals Company Information
  93. 8.16.2 Hikma Pharmaceuticals Business Overview
  94. 8.16.3 Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hikma Pharmaceuticals Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  96. 8.16.5 Hikma Pharmaceuticals Recent Developments
  97. 8.17 Dr. Reddy's Laboratories
  98. 8.17.1 Dr. Reddy's Laboratories Company Information
  99. 8.17.2 Dr. Reddy's Laboratories Business Overview
  100. 8.17.3 Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Dr. Reddy's Laboratories Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  102. 8.17.5 Dr. Reddy's Laboratories Recent Developments
  103. 8.18 Cipla
  104. 8.18.1 Cipla Company Information
  105. 8.18.2 Cipla Business Overview
  106. 8.18.3 Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Cipla Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  108. 8.18.5 Cipla Recent Developments
  109. 8.19 Celltrion
  110. 8.19.1 Celltrion Company Information
  111. 8.19.2 Celltrion Business Overview
  112. 8.19.3 Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Celltrion Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  114. 8.19.5 Celltrion Recent Developments
  115. 8.20 Astellas Pharma Inc. (Japan)
  116. 8.20.1 Astellas Pharma Inc. (Japan) Company Information
  117. 8.20.2 Astellas Pharma Inc. (Japan) Business Overview
  118. 8.20.3 Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Astellas Pharma Inc. (Japan) Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae Product Portfolio
  120. 8.20.5 Astellas Pharma Inc. (Japan) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst